| Antagonism between bacteriostatic and bactericidal antibiotics is prevalent PS Ocampo, V Lázár, B Papp, M Arnoldini, P Abel zur Wiesch, ... Antimicrobial agents and chemotherapy 58 (8), 4573-4582, 2014 | 302 | 2014 |
| Population biological principles of drug-resistance evolution in infectious diseases PA Zur Wiesch, R Kouyos, J Engelstädter, RR Regoes, S Bonhoeffer The Lancet infectious diseases 11 (3), 236-247, 2011 | 286 | 2011 |
| Compensation of fitness costs and reversibility of antibiotic resistance mutations P Schulz zur Wiesch, J Engelstadter, S Bonhoeffer Antimicrobial agents and chemotherapy 54 (5), 2085-2095, 2010 | 202 | 2010 |
| Bi-modal Distribution of the Second Messenger c-di-GMP Controls Cell Fate and Asymmetry during the Caulobacter Cell Cycle S Abel, T Bucher, M Nicollier, I Hug, V Kaever, P Abel zur Wiesch, U Jenal PLoS genetics 9 (9), e1003744, 2013 | 145 | 2013 |
| Analysis of bottlenecks in experimental models of infection S Abel, P Abel zur Wiesch, BM Davis, MK Waldor PLoS pathogens 11 (6), e1004823, 2015 | 125 | 2015 |
| Genetic analysis of Vibrio parahaemolyticus intestinal colonization TP Hubbard, MC Chao, S Abel, CJ Blondel, P Abel zur Wiesch, X Zhou, ... Proceedings of the National Academy of Sciences 113 (22), 6283-6288, 2016 | 108 | 2016 |
| The path of least resistance: aggressive or moderate treatment? RD Kouyos, CJE Metcalf, R Birger, EY Klein, P Abel zur Wiesch, ... Proceedings of the Royal Society B: Biological Sciences 281 (1794), 20140566, 2014 | 103 | 2014 |
| Cycling empirical antibiotic therapy in hospitals: meta-analysis and models P Abel zur Wiesch, R Kouyos, S Abel, W Viechtbauer, S Bonhoeffer PLoS pathogens 10 (6), e1004225, 2014 | 96 | 2014 |
| Sequence tag–based analysis of microbial population dynamics S Abel, P Abel zur Wiesch, HH Chang, BM Davis, M Lipsitch, MK Waldor Nature methods 12 (3), 223-226, 2015 | 93 | 2015 |
| Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis A Kunkel, P Abel zur Wiesch, RR Nathavitharana, FM Marx, HE Jenkins, ... BMC infectious diseases 16, 1-9, 2016 | 82 | 2016 |
| Classic reaction kinetics can explain complex patterns of antibiotic action P Abel Zur Wiesch, S Abel, S Gkotzis, P Ocampo, J Engelstädter, ... Science translational medicine 7 (287), 287ra73-287ra73, 2015 | 80 | 2015 |
| Deciphering the landscape of host barriers to Listeria monocytogenes infection T Zhang, S Abel, P Abel zur Wiesch, J Sasabe, BM Davis, DE Higgins, ... Proceedings of the National Academy of Sciences 114 (24), 6334-6339, 2017 | 67 | 2017 |
| On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community RD Kouyos, P Abel zur Wiesch, S Bonhoeffer PLoS pathogens 7 (4), e1001334, 2011 | 50 | 2011 |
| Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards RD Kouyos, P Abel zur Wiesch, S Bonhoeffer PLoS computational biology 7 (3), e1001094, 2011 | 50 | 2011 |
| Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study PP Salvatore, MC Becerra, P Abel zur Wiesch, T Hinkley, D Kaur, ... The Journal of infectious diseases 213 (1), 149-155, 2016 | 46 | 2016 |
| Transposon-insertion sequencing screens unveil requirements for EHEC growth and intestinal colonization AR Warr, TP Hubbard, D Munera, CJ Blondel, P Abel zur Wiesch, S Abel, ... PLoS pathogens 15 (8), e1007652, 2019 | 39 | 2019 |
| The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB D Cadosch, P Abel zur Wiesch, R Kouyos, S Bonhoeffer PLoS computational biology 12 (3), e1004749, 2016 | 34 | 2016 |
| Using chemical reaction kinetics to predict optimal antibiotic treatment strategies P Abel zur Wiesch, F Clarelli, T Cohen PLoS computational biology 13 (1), e1005321, 2017 | 26 | 2017 |
| Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota B Tepekule, P Abel zur Wiesch, RD Kouyos, S Bonhoeffer Proceedings of the National Academy of Sciences 116 (46), 23106-23116, 2019 | 24 | 2019 |
| Multi-scale modeling of drug binding kinetics to predict drug efficacy F Clarelli, J Liang, A Martinecz, I Heiland, P Abel zur Wiesch Cellular and Molecular Life Sciences 77, 381-394, 2020 | 22 | 2020 |
Sören AbelForsker, Department for Bacteriology, Norwegian Institute of Public HealthVerified email at fhi.no
